


# Gut Microbiome–Wide Search for Bacterial Azoreductases Reveals Potentially Uncharacterized Azoreductases Encoded in the Human Gut Microbiome<sup>§</sup>

 Domenick J. Braccia, Glory Minabou Ndjite, Ashley Weiss, Sophia Levy, Stephenie Abeysinghe, Xiaofang Jiang, Mihai Pop, and Brantley Hall

Center for Bioinformatics and Computational Biology (D.B., M.P., B.H.) and Departments of Cell Biology and Molecular Genetics (G.M.N., A.W., S.L., S.A., B.H.) and Computer Science (M.P.), University of Maryland, College Park, Maryland; and National Library of Medicine, National Institutes of Health, Bethesda, Maryland (X.J.)

Received March 14, 2022; accepted August 18, 2022

## ABSTRACT

The human gut is home to trillions of microorganisms that are responsible for the modification of many orally administered drugs, leading to a wide range of therapeutic outcomes. Prodrugs bearing an azo bond are designed to treat inflammatory bowel disease and colorectal cancer via microbial azo reduction, allowing for topical application of therapeutic moieties to the diseased tissue in the intestines. Despite the inextricable link between microbial azo reduction and the efficacy of azo prodrugs, the prevalence, abundance, and distribution of azoreductases have not been systematically examined across the gut microbiome. Here, we curated and clustered amino acid sequences of experimentally confirmed bacterial azoreductases and conducted a hidden Markov model–driven homolog search for these enzymes across 4644 genome sequences present in the representative Unified Human Gastrointestinal Genomes collection. We identified 1958 putative azo-reducing species, corroborating previous findings that azo reduction appears to be a ubiquitous function of the gut microbiome. However, through a systematic

comparison of predicted and confirmed azo-reducing strains, we hypothesize the presence of uncharacterized azoreductases in 25 prominent strains of the human gut microbiome. Finally, we confirmed the azo reduction of Acid Orange 7 by multiple strains of *Fusobacterium nucleatum*, *Bacteroides fragilis*, and *Clostridium clostridioforme*. Together, these results suggest the presence and activity of many uncharacterized azoreductases in the human gut microbiome and motivate future studies aimed at characterizing azoreductase genes in prominent members of the human gut microbiome.

## SIGNIFICANCE STATEMENT

This work systematically examined the prevalence, abundance, and distribution of azoreductases across the healthy and inflammatory bowel disease human gut microbiome, revealing potentially uncharacterized azoreductase genes. It also confirmed the reduction of Acid Orange 7 by strains of *Fusobacterium nucleatum*, *Bacteroides fragilis*, and *Clostridium clostridioforme*.

## Introduction

Orally administered drugs are an attractive, noninvasive mode of delivery of pharmaceuticals to the intestines. The human gut microbiome plays an important role in drug metabolism (Spanogiannopoulos et al., 2016) and is capable of activating (Peppercorn and Goldman, 1972; Morrison et al., 2012; Sousa et al., 2014), inactivating (Peters, 1978;

Saha et al., 1983; Haiser et al., 2013), and even toxifying (Wallace et al., 2010) pharmaceutical drugs. Prodrugs containing an azo bond actually require bacterial azoreductase activity to release biologically active compounds (Peppercorn and Goldman, 1972). For conditions such as inflammatory bowel disease (IBD) and colorectal cancer (CRC), bacterial azoreductases have been used to deliver therapeutics such as 5-aminosalicylic acid (5-ASA), prednisolone (Ruiz et al., 2011), and celecoxib (Ruiz et al., 2011) topically to diseased intestinal tissues (Fig. 1). Following oral administration of sulfasalazine, bacterial azoreductases in the gut reduce azo bonds, liberating 5-ASA and allowing it to confer its anti-inflammatory properties (Mahida et al., 1991; Rachmilewitz et al., 1992; Weber et al., 2000) topically on inflamed intestinal tissue. Direct oral administration of 5-ASA is nonoptimal because the majority of the drug is absorbed in the small intestine and is sent through systemic circulation (Peppercorn and Goldman, 1973; Tozaki et al., 2002; Friend, 2005; Perrotta et al., 2015; Foppoli et al., 2019). Other examples of azo-bonded prodrugs are OPN501 and celecoxib-5-ASA. OPN501 is made of up prednisolone, 5-ASA, and an inert cyclization product, dihydroquinolone


D.B. was supported in part by the National Science Foundation [DGE-1632976] and in part by B.H. startup funding from the University of Maryland. X.J. was supported in part by the Intramural Research Program of National Institutes of Health National Library of Medicine. M.P. was supported by National Institutes of Health [Grant R01-AI-100947]. B.H., G.M.N., A.W., S.L., and S.A. were supported by startup funding from the University of Maryland.

No author has an actual or perceived conflict of interest with the contents of this article.

dx.doi.org/10.1124/dmd.122.000898.

<sup>§</sup> This article has supplemental material available at [dmd.aspetjournals.org](http://dmd.aspetjournals.org).

**ABBREVIATIONS:** 5-ASA, 5-aminosalicylic acid; BHI, Brain Heart Infusion; CD, Crohn disease; CRC, colorectal cancer; DHQ, dihydroquinolone; EFI-EST, Enzyme Function Initiative-Enzyme Similarity Tool; FDR, false discover rate; FMN, flavin mononucleotide; FN, false negative; FP, false positive; HMM, hidden Markov model; HMP2, Integrative Human Microbiome Project; HPFS, Health Professionals Follow-Up Study; IBD, inflammatory bowel disease; PR, predicted reducer; PRISM, Prospective Registry of IBD Patients at MGH; SR, sulfasalazine reducing; TN, true negative; TP, true positive; UC, ulcerative colitis; UHGG, Unified Human Gastrointestinal Genomes; YCFA, Yeast Casitone Fatty Acid.



**Fig. 1.** Azo reduction by gut microbiota. (A) Pathways of azo-bonded drug activation by bacterial azoreductase activity. DHQ is produced via cyclization of an intermediate of OPN501 and celecoxib-5-ASA prodrug following intramolecular lactamization (Ruiz et al., 2011). (B) Description of downstream metabolites of bacterial azo reduction and the mechanisms of action in IBD and CRC. References for each molecular function described in this subfigure: 5-ASA (Mahida et al., 1991; Cominelli et al., 1992; Rachmilewitz et al., 1992), prednisolone (Cohen et al., 2000), celecoxib (Wu et al., 2003; Wu et al., 2010; Gustafsson et al., 2010), sulfapyridine (Nielsen, 1982), and DHQ (Ruiz et al., 2011). (C) Presence of azoreductase-containing bacteria is required for prodrug activation in the IBD gut and CRC gut (left). Many azo-reducing bacteria have been characterized; however, some species have shown experimental evidence of azo-reduction without the full characterization of the genes responsible for azo reduction (right).

(DHQ). Upon azo reduction, 5-ASA is released and is able to act topically upon the target tissue. Following a spontaneous cyclization reaction, prednisolone and DHQ are released where prednisolone can act upon the target tissue (Ruiz et al., 2011). Celecoxib-5-ASA is made up of celecoxib, 5-ASA, and DHQ, which are all released upon azo reduction and cyclization in a similar mechanistic fashion to OPN501 (Ruiz et al., 2011).

A recent review article by Suzuki (2019) collected and curated experimentally confirmed azoreductases and described their preferred flavin cofactors and electron donors. They found that bacterial azoreductases qualitatively cluster into four main clades, which harbor a preference for either flavin mononucleotide (FMN) or flavin adenine dinucleotide as the flavin cofactor and either NADH or NADPH as the preferred

electron donor. Clades I, II, and III are flavoproteins, whereas clade IV proteins are flavin free. Clade I azoreductases prefer NADPH as the electron donor, clade II prefers NADH as its electron donor, and clades III and IV generally use both. Of the 37 enzymes examined by Suzuki (2019), eight enzymes formed no distinct phylogenetic clade and featured differences in primary sequence length, flavin cofactor, and preferred electron donor. In addition to their relevance in drug delivery and efficacy, azoreductases are involved in nitroreduction (Brown 1981; Rafii et al., 1990; Rafii and Cerniglia, 1995; Liu et al., 2007; Mercier et al., 2013; Chalansonnet et al., 2017), quinone oxidoreduction (Liu et al., 2008; Leelakriangsak et al., 2008; Ryan et al., 2010a; Ryan et al., 2010b; Ryan et al., 2014), and azo dye reduction. Azo dyes such as Allura

Red and Brilliant Black are commonly used in the food and textile industries, and waste from their production and usage pollutes the environment. This has led to a plethora of manuscripts characterizing the activity of azoreductases across the bacterial kingdom (Cerniglia et al., 1982; Zimmermann et al., 1982; Nakanishi et al., 2001; Suzuki et al., 2001; Blümel et al., 2002; Blümel and Stolz, 2003; Chen et al., 2004; Chen et al., 2005; Nachiyar and Rajakumar, 2005; Ooi et al., 2007; Matsumoto et al., 2010; Misal et al., 2011; Feng et al., 2012; Gonçalves et al., 2013; Lang et al., 2013; Misal et al., 2014; Eslami et al., 2016; Zhang et al., 2016), many of which exhibit nonnegligible sequence similarity to gut microbial azoreductases (Suzuki 2019).

There is a growing body of literature suggesting that azo reduction is a ubiquitous function of the human gut microbiome (Javdan et al., 2020), with many prominent bacterial strains showing significant reduction of sulfasalazine in vitro (Zimmermann et al., 2019). Javdan et al. (2020) showed that among 20 different individuals, sulfasalazine reduction was one of the only ubiquitous functions of the gut microbiome. Zimmermann et al. (2019) tested the reduction of sulfasalazine by 76 prominent strains of the gut microbiome and reported a significant [false discover rate (FDR) adjusted  $P$  value < 0.05] reduction of sulfasalazine by 62 of these strains. Interestingly, some of these experimentally confirmed azo-reducing strains reported by Zimmermann et al. (2019) have no prior evidence of azo-reduction and, thus, may encode novel or uncharacterized azoreductase genes (Fig. 1C). Identification of known azoreductases in newly reported sulfasalazine-reducing species can help narrow down strains to target for identification of uncharacterized azoreductases.

The prevalence, abundance, expression, and distribution of azoreductase enzymes in the human gut microbiome have implications for the efficacy of existing prodrugs mentioned above, as well as for the development of future azo prodrugs. Although azoreductases have been identified and characterized in many gut bacteria (Supplemental Table 1), the distribution of azoreductases has not been systematically explored across current gut bacterial reference genomes. To address this gap, we conducted a homolog search of known azoreductases across the Unified Human Gastrointestinal Genomes (UHGG) collection (Almeida et al., 2020) to identify putative azoreductases and azo-reducing species in the human gut microbiome. We then assessed the relative abundance and expression of known azoreductases in healthy, ulcerative colitis (UC), and Crohn disease (CD) participants of the Integrative Human Microbiome Project (HMP2) (Proctor and Huttenhower, 2019), the Prospective Registry of IBD Patients at MGH (PRISM) (Franzosa et al., 2019), and the Health Professionals Follow-Up Study (HPFS) (Abu-Ali et al., 2018). Finally, we tested the in vitro azo reduction of Acid Orange 7 by three strains of *Fusobacterium nucleatum* along with two strains of *Bacteroides fragilis* and two strains of *Clostridium clostridioforme*.

## Materials and Methods

**Description of Publicly Available Shotgun Metagenomic Sequencing Data.** Shotgun metagenomic sequencing data obtained from the HMP2 [N (samples) = 703, N (individuals) = 103] (Proctor and Huttenhower, 2019), the PRISM [N (samples) = 218, N (individuals) = 218] (Franzosa et al., 2019), and the HPFS [N (samples) = 220, N (individuals) = 220] (Abu-Ali et al., 2018) are used throughout this work. Note that all samples referred to throughout this work are human stool samples.

**Curation of Hidden Markov Models Representing Azoreductase Enzymes.** We searched the literature for known and experimentally validated species of bacteria that have azoreductase activity. The list of gene sequences collected, along with the relevant metadata (organism, functional annotation, length, etc.) is available in Supplemental Table 1. Preliminary evidence for

azoreductase gene sequence clustering is shown in Suzuki (2019), where sequences were aligned and phylogenetically compared. Next, after collecting 40 sequences of experimentally validated azoreductases, we generated a sequence similarity network using the Enzyme Function Initiative-Enzyme Similarity Tool (EFI-EST) (Gerlt et al., 2015) at a 35% amino acid sequence identity threshold for identifying similar clusters of azoreductase genes. This threshold corroborates the preliminary evidence for a diversity of azoreductase sequences put forth by Suzuki (2019). With the exception of clade IVb sequences, which reached 31% sequence identity, all other clusters of genes had at least 35% sequence identity. The groups shown in Fig. 2 were pressed into profile hidden Markov models (HMMs) using HMMER v[N/A]/N/A/jersion 3.1b2 (Finn et al., 2015). Other genes that did not fall into the clade I–clade IV clusters (*arsH*, *yieF*, *mdaB*, *azo1*, *azoR*, etc.) were pressed into singular HMMs and included in the homolog search.


**Search for Azoreductase Genes across Human Gut Microbial Genomes.** We searched HMMs of known, experimentally validated azoreductases across 4644 nonredundant genomes contained in the UHGG collection (Almeida et al., 2020) using HMMER v3.1b2 (Finn et al., 2015). Alignments to queried HMMs with E-value <  $1 \times 10^{-10}$  and 60% coverage of the query sequence were labeled as putative azoreductase gene sequences. Putative azoreducing bacterial species with experimentally confirmed azoreductase activity (Supplemental Table 2) were then labeled as “known” azo-reducing species and classified separately from the putative azo-reducing species. Putative azoreducing species across the bacterial taxonomy were visualized using the iTOL web interface (Letunic and Bork, 2019), and prominent phyla of the gut microbiome were subsetted and presented in Fig. 3.

**Relative Abundance and Azoreductase Gene Abundance and Expression Estimation.** Raw sequencing reads for samples from HMP2 (Proctor and Huttenhower, 2019), PRISM (Franzosa et al., 2019), and HPFS (Abu-Ali et al., 2018) were downloaded and extracted with the National Center for Biotechnology Information’s SRA toolkit v2.10.9 (<http://ncbi.github.io/sra-tools/>). Quality control and adapter trimming of the fastq sequence files were done with the Trim Galore wrapper v0.6.6 ([https://www.bioinformatics.babraham.ac.uk/projects/trim\\_galore/](https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)). To remove potential human contaminants, quality trimmed reads were screened against the human genome (hg19) with Bowtie2 v2.4.2 (Langmead and Salzberg, 2012). Putative azoreductase sequences were extracted from UHGG genomes via custom shell and python scripts. Putative azoreductase gene sequences (HMP2, PRISM) and expression levels (HPFS) were quantified using salmon v1.4.0 (Patro et al., 2017) and were normalized and aggregated in R v4.1.1 and were subsequently visualized using the R package ggplot2 (Wickham, 2011) (Fig. 4). Taxonomy profiling of the cleaned metagenomic reads from HMP2 samples was performed using Kraken 2 v2.0.8-beta (Wood et al., 2019) to estimate the relative abundance of bacterial species present in each dataset. These relative abundances were then processed in R v4.1.1 and plotted using ggplot2 (Fig. 5). All computational and bioinformatic procedures are open source and are provided at <https://github.com/dombraccia/Azoreductases>.

**Statistical Analysis of Relative Metagenomic Sequence Data from HMP2 and PRISM Datasets.** Statistical analyses described in Fig. 4 were performed in R 4.1.1 with the Wilcoxon test method using default parameterization. Next, we compared the relative abundances of known and putative azo-reducing species for HMP2 subjects with 20 or more stool samples taken over the course of the study (Fig. 5). A linear mixed-effects model ANOVA was performed on this subset of HMP2 data to determine any statistically significant differences in relative abundance values across non-IBD, UC, and CD subjects. The R package lme4 (Bates et al., 2014) was used to fit the model to the data, and the package lmerTest (Kuznetsova et al., 2017) was used to perform the ANOVA on the model. All statistical analyses were performed in R version 4.1.1 and are provided at <https://github.com/dombraccia/Azoreductases>.

**Acid Orange 7 Azo Reduction Assay.** Biologic triplicates were grown in a 10 ml tube containing 10 ml of Yeast Casitone Fatty Acids (YCFA) broth for *B. fragilis* and *C. clostridioforme* strains and 10 ml of Brain Heart Infusion (BHI) broth for *F. nucleatum* strains. Each tube was inoculated with 10  $\mu$ L of bacteria from glycerol stocks. The final concentrations of each substrate in the bacterial cultures were 50  $\mu$ g/ml of FMN, 50  $\mu$ g/ml of NADH, and 50  $\mu$ mol/ml of Acid Orange 7. The bacterial cultures were left to grow in an anaerobic chamber for 72 hours, and Acid Orange 7 decolorization was measured once every 24 hours since inoculation. The decolorization of Acid Orange 7 was measured by aliquoting triplicates of 200  $\mu$ L media aliquants to a 96-well plate for each bacterial culture, and absorbance of 550 nm light was measured using a spectrophotometer.





**Fig. 2.** Bacterial azoreductases cluster by cofactor and electron donor preferences. Following an extensive literature search for experimentally confirmed bacterial azoreductases, amino acid sequences of 40 azoreductase enzymes were collected and clustered with EFI-EST (Gerlt et al., 2015) at 35% sequence identity. Each node in the figure above is a single azoreductase gene, and the edges between nodes indicate at least 35% sequence identity between the two amino acid sequences. The colored clusters, clade I through clade IVa and IVb, are groups of azoreductases previously described by Suzuki (2019) as mechanistically similar groups based on cofactor and electron donor preferences. Clusters labeled with gene names (*mdaB*, *yieF*, etc.) represent homologous gene sequences found in two or more organisms. Each mechanistically characterized group of azoreductases were subsequently pressed into profile HMMs using HMMER v3.1b2 (Finn et al., 2015), which formed the basis of the homolog search. The group labeled “other azoreductases” contains sequences that did not fall into any cluster at the 35% identity threshold and were pressed into singular HMMs prior to the homolog search.


The raw absorbance values for each biologic and technical replicate are reported in Supplemental Table 5.

## Results

**Primary Amino Acid Sequences of Bacterial Azoreductases Group by Mechanistic Preferences.** To begin identifying putative azo-reducing species of the gut microbiome, we searched the literature for experimentally verified azoreductase enzymes, collected amino acid sequences, and metadata for these azoreductases (Supplemental Table 1) and compared their primary sequences using the EFI-EST (Gerlt et al., 2015). The resulting sequence similarity network captured mechanistic preferences such as flavin dependence and electron donor preference for each azoreductase reported by Suzuki (2019). We saw near-complete concordance between the clade I–IV azoreductases and the sequence similarity clusters at a 35% amino acid identity edge threshold, with the exception of clade IV, which was split into two separate clusters (Fig. 2). The gene families labeled *arsH*, *mdaB*, *yieF*, and *azo1* clustered separately from clade I–IV azoreductases, and we consider each of these clusters as separate subfamilies of azoreductases. Multiple sequence alignments were generated for each cluster shown in Fig. 2 (with the exception of the “Other Azoreductases” group) using MUSCLE v3.8.425 (Edgar, 2004). HMMs were then trained on the multiple sequence alignments from the previous

step using the HMMER v3.1b2 method hmmpress (Finn et al., 2015) and were queried against the UHGG collection (Almeida et al., 2020).

**Homolog Search for Azoreductases Supports Evidence for Ubiquity of Azo Reduction by the Human Gut Microbiome.** We searched for homologs of azoreductases across 4644 representative genomes in the UHGG collection (Almeida et al., 2020) using HMMs generated from sequences of experimentally validated azoreductase enzymes (Fig. 3). This collection contains 204,938 genome sequences of bacteria known to inhabit the human gut, of which 4644 are included in the representative collection (Supplemental Table 4). For the remainder of this work, we refer to species receiving statistically significant ( $E\text{-value} < 1 \times 10^{-10}$ ) hits to azoreductase genes as “putative azo-reducing species” or “putative azo-reducing bacteria.” Of the 4644 genomes in the UHGG collection, there are 1443 (31.1%) with one putative azoreductase gene, 343 (7.4%) with two or more putative azoreductases, and 372 (8.0%) with three or more putative azoreductases, indicating the extensive potential of the gut microbiome to reduce azo bonds. Most notably, 364 genomes contain hits to the clade I profile, 452 contain hits to the clade II profile, 793 genomes contain hits to the clade III profile, 568 contain hits to the clade IVa profile, 410 contain hits to the clade IVb profile, 285 contain hits to the *mdaB* profile, and 477 contain hits to the *yieF* profile. Prominent phyla of the gut microbiome, such as *Proteobacteria* and *Firmicutes*, appear particularly rich with clade I, clade II, clade III, clade




**Fig. 3.** Azoreductases are widely distributed across gut bacterial taxonomy. Presence/absence of azoreductases across prominent phyla of the human gut microbiome. The taxonomic tree is obtained from the UHGG (Almeida et al., 2020) which is built on the Genome Taxonomy Database (Chaumeil et al., 2019). Phyla names are annotated on the left side. Phyla names followed by a capital letter, e.g., Firmicutes (A), indicate a novel phylum classified by the Genome Taxonomy Database toolkit. The bar chart in the center indicates the number of species contained in each genus shown in the tree. The size of the circles indicates the number of species that contain hits to the azoreductase genes specified. The color of the circles indicates the cofactor and preferred electron ( $e^-$ ) donor of the enzyme.

IVab, and flavin adenine dinucleotide utilizing azoreductases (purple columns in Fig. 3).

**Systematic Evaluation of Predicted Azo-Reducing Species.** We next sought to evaluate the results of our azoreductase homolog search with recent findings by Zimmermann et al. (2019) regarding sulfasalazine reduction. Zimmermann et al. (2019) tested the degradation of sulfasalazine by 76 prominent gut bacterial strains, 67 of which had corresponding reference genomes present in the UHGG collection. This provided an excellent source of data to compare our bioinformatic predictions against. We determined the sulfasalazine-reducing status as either sulfasalazine reducing (SR) or non-sulfasalazine reducing for each of the 67 strains based on the significant (FDR adjusted  $P$  value < 0.05) reduction of

sulfasalazine in vitro reported by Zimmermann et al. (2019) (Table 1). We also determined the predicted reducing status as either a predicted reducer (PR) or a non-predicted reducer (Non-PR) for each strain based on the presence of a putative azoreductase identified from the homolog search step. For each strain, the sulfasalazine-reducing status and predicted reducing status were systematically compared to validate the results of the azoreductase homolog search (Table 1, columns 7–9). We correctly predicted the sulfasalazine-reducing status for 47.8% (32/67) of strains and we incorrectly predicted the sulfasalazine reducing status for 52.2% (35/67) of strains (Table 2). The vast majority (77.1%, 27/35) of incorrectly predicted strains are false negatives, meaning the strain does reduce sulfasalazine in vitro, but we did not identify an azoreductase in



**Fig. 4.** Abundance and expression of azoreductase genes by human gut microbiota. (A and B) Visualization of shotgun metagenomic sequencing data from the Human Microbiome Project 2, also known as the HMP2 and the PRISM. We used salmon 1.4.0 (Patro et al., 2017) to quantify the abundance of azoreductase genes from hundreds of stool samples across healthy controls (non-IBD), UC, and CD participant cohorts. Raw DNA read alignment counts were normalized to counts per million (CPM), analogous to transcripts-per-million (TPM) normalization. Asterisks above each boxplot indicate statistical significance (\* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ , Wilcoxon rank sum test, all FDR adjusted using Benjamini-Hochberg method). (C) Visualization of high-throughput metatranscriptomic data obtained from the HPFS. We quantified the expression of bacterial azoreductases using salmon v1.4.1 (Patro et al., 2017) and normalized the raw read alignment statistics to transcripts per million (TPM). Please see *Materials and Methods* for a more detailed description of the computational and statistical methods employed.

the homolog search step (Table 2). Interestingly, the majority of false positives (75%, 6/8) are members of the Proteobacteria phylum, which we previously noted to be particularly rich in azoreductase gene sequences (Fig. 3).


**Exploratory Analysis of Azoreductase Abundance and Expression Levels in the Human Gut Microbiome.** After identifying putative azo-reducing species of the human gut microbiome, we next sought to examine the abundance and expression of putative azoreductases using publicly available metagenomic and metatranscriptomic datasets. We used shotgun metagenomic sequence data from the HMP2 (Proctor and Huttenhower, 2019) and the PRISM (Franzosa et al., 2019) to quantify azoreductase gene abundance. We also used high-throughput metatranscriptomic sequence data from the HPFS (Abu-Ali et al., 2018) to quantify the expression of azoreductases by the human gut microbiota (Fig. 4, A–C). Briefly, raw genomic and transcriptomic reads were filtered and processed using fastp (Chen et al., 2018), and

azoreductases were quantified using salmon v1.4.0 (Patro et al., 2017). Please see *Materials and Methods* for more details on the computational and statistical procedures used.

Significant differences in azoreductase gene abundances between disease conditions are displayed in Fig. 4, A and B with asterisks. We find that clade I, clade II, clade III, clade IVa, clade IVb, mdaB, and yieF genes are considerably higher in abundance than ferB, azoR1\_cperf, arsH, azoR\_ropacus, azo1, and azoR1\_llentus within all three disease conditions for both HMP2 (all FDR adjusted  $P < 2.2 \times 10^{-16}$ ) and PRISM (all FDR adjusted  $P < 2.6 \times 10^{-7}$ ) (Fig. 4, A and B). Clade IVa is higher in abundance than all other azoreductases across healthy, UC, and CD cohorts from HMP2 (Fig. 4A), but the same statistically significant difference was not observed in the PRISM study (Fig. 4B).

The expression of clade I, clade II, clade III, clade IVa, mdaB, and yieF azoreductases are significantly higher than those of clade IVb, ferB, azoR1\_cperf, arsH, azoR\_ropacus, azo1, and azoR1\_llentus azoreductases





**Fig. 5.** Known and putative azo-reducing species are more abundant in the IBD gut. Relative abundance of known and putative azo-reducing species in HMP2 subjects with more than 20 total stool collections. (A) Relative abundance of known and putative azo-reducing species for qualifying participants across non-IBD, UC, and CD populations. Subjects with CD have significantly higher relative abundances of known+putative azo-reducing species than healthy subjects (non-IBD) per linear mixed-effects model ANOVA,  $F(1,10) = 17.09, P < 0.003$ . (B) Relative abundance of putative azo-reducing species over time for healthy (non-IBD), UC, and CD participants. Each line represents a single participant, and each point is the summed relative abundance of known+putative azo-reducing species at that collection point. The key on the right links relative abundance distributions for each subject with the same data point shown over collection numbers. Collections were taken approximately every 14 days.

in healthy individuals (minimum FDR adjusted  $P$  value  $< 1 \times 10^{-7}$  between *mdaB* and *azoR1\_cperf*) (Fig. 4C). Although clade IVb abundance levels are comparable to those of clades I, II, III, and IVa, the expression levels of clade IVb azoreductases are significantly lower in vivo than the expression clade I, II, III, and IVa azoreductases (all FDR adjusted  $P < 2.2 \times 10^{-16}$ ).

**The Relative Abundance of Putative Azo-Reducing Species Fluctuates over Time.** We next sought to examine whether relative abundance levels of combined known and putative azo-reducing species are stable or fluctuate over time. The HMP2 dataset provides a unique opportunity to examine the stability of individuals' gut microbiomes over time as there are 18 individuals across healthy, UC, and CD cohorts, with at least 20 stool samples taken once every 2 weeks over a 6-month period. To examine the stability of azo reduction in the human gut, we compared the relative abundance of known and putative azo-reducing species from these participants (Fig. 5). The median relative abundance of combined azo-reducing species ranges from  $20.3 \pm 3.58\%$  to  $33.9 \pm 19.2\%$  for non-IBD,  $21.7 \pm 7.6\%$  to  $49.0 \pm 15.0\%$  for UC, and  $34.9 \pm 6.39$  to  $62.3 \pm 18.8$  for CD subjects. Using linear mixed-effects model ANOVA, we found that combined azo-reducing species are significantly more abundant in CD subjects than in non-IBD subjects ( $P = 0.002$ ) and are not significantly more abundant in UC subjects than in non-IBD subjects ( $P = 0.064$ ) (Fig. 5A). Note that Fig. 5B shows the same relative abundance values displayed in Fig. 5A but over the course of the study, from collection 1 to collection 24.

**Multiple Strains of *F. Nucleatum*, *B. Fragilis*, and *C. Clostridioforme* Reduce Acid Orange 7 in Vitro.** Finally, we sought to test the azo reduction of Acid Orange 7 by three strains of the health-relevant (Castellari et al., 2012; Kostic et al., 2012; Bashir et al., 2015; Abed et al., 2016) microbe *F. nucleatum*. As well, we tested the azo reduction of Acid Orange 7 by two positive control species, *B. fragilis* and *C. clostridioforme*. Acid Orange 7 is an azo-bonded dye commonly used in the food and textile industries (Bay et al., 2014), and the decolorization of azo-bonded dyes is commonly used to test azo reduction by bacteria in vitro (Feng et al., 2012). *F. nucleatum* CTI-06, *F. nucleatum* subsp. *animalis* D11, and *F. nucleatum* subsp. *polymorphum* were grown in BHI media, and Acid Orange 7 was added to the culture after 4 days of growth (Materials and Methods). We also tested the azo reduction of Acid Orange 7 by the known azo-reducing species *B. fragilis* and *Clostridium clostridioforme*. *B. fragilis* strains 3\_1\_12 and CL07T00C01 and *C. clostridioforme* strains 2\_1\_49\_FAA and WAL-7855 were grown in YCFA broth and served as positive controls. We found that all strains examined in this assay significantly decolorized Acid Orange 7 in vitro (Fig. 6). To our knowledge, this is the first reporting of azo reduction by *F. nucleatum* CTI-06, *F. nucleatum* subsp. *animalis* D11, and *F. nucleatum* subsp. *polymorphum*.

## Discussion

The presence of azo-reducing bacteria in the human gut is necessary for the effective delivery and activation of azo-bonded prodrugs.

TABLE 1

Systematic comparison with Zimmermann et al. (2019) sulfasalazine consumption results

Complete results from the systematic comparison of predicted sulfasalazine-reducing bacteria to actual sulfasalazine-reducing bacteria. The columns labeled FC (fold change), FC\_STD (standard deviation in fold change), P\_FDR (FDR adjusted P value), Pct\_Consumed (percent consumed), and Pct\_Consumed\_STD (standard deviation of the percent consumed) were all obtained directly from Zimmermann et al. (2019) (Supplemental Table 3). The SR\_Status column contains values SR and non-SR, which were determined based on significant ( $p\_FDR < 0.05$ ) or nonsignificant ( $p\_FDR \geq 0.05$ ) sulfasalazine reduction. The PR\_Status column contains the values PR and non-PR, which were determined based on the presence or absence of one or more azoreductase homologs determined from the homolog search step. The final column, Result, contains the values TP (true positive), TN (true negative), FP (false positive), and FN (false negative). Correctly predicted SR strains have a result of TP and correctly predicted Non-SR strains have a result of TN whereas incorrectly predicted SR strains have a result of FP and incorrectly predicted Non-SR strains have a result of FN.

Strain_Name	FC	FC_STD	p_FDR	Pct_Consumed	Pct_Consumed_STD	SR_Status	PR_Status	Result
<i>Akkermansia muciniphila</i> ATCCBAA-835	-0.419	0.361	0.19	25.222	18.707	Non-SR	Non-PR	TN
<i>Alistipes indistinctus</i> DSM 22520	-9.01	0.11	0.003	99.806	0.015	SR	PR	TP
<i>Anaerococcus hydrogenalis</i> DSM7454	-8.826	0.198	0.008	99.78	0.03	SR	Non-PR	FN
<i>Anaerotruncus colihominis</i> DSM17241	-8.088	1.575	0.016	99.633	0.401	SR	Non-PR	FN
<i>Bacteroides caccae</i> ATCC43185	-9.247	0.262	0.008	99.835	0.03	SR	PR	TP
<i>Bacteroides cellulosilyticus</i> DSM14838	-1.502	0.308	0.002	64.691	7.532	SR	PR	TP
<i>Bacteroides coprophilus</i> DSM18228	-0.006	0.216	0.991	0.386	14.918	Non-SR	Non-PR	TN
<i>Bacteroides dorei</i> DSM17855	-4.631	0.748	0.013	95.965	2.091	SR	Non-PR	FN
<i>Bacteroides eggerthii</i> DSM20697	-9.59	0.104	0.002	99.87	0.009	SR	Non-PR	FN
<i>Bacteroides finegoldii</i> DSM17565	-0.79	0.296	0.042	42.176	11.877	SR	Non-PR	FN
<i>B. fragilis</i> 3397 T10	-0.974	0.348	0.009	49.084	12.282	SR	PR	TP
<i>B. fragilis</i> ATCC43859	-10.576	0.088	0.003	99.934	0.004	SR	PR	TP
<i>B. fragilis</i> DS-208	-9.327	0.57	0.006	99.844	0.062	SR	PR	TP
<i>B. fragilis</i> HMW610	-10.522	0.159	0.004	99.932	0.007	SR	PR	TP
<i>B. fragilis</i> HMW615	-10.398	0.256	0.013	99.926	0.013	SR	PR	TP
<i>B. fragilis</i> NCTC9343	-6.184	0.835	0.006	98.625	0.796	SR	PR	TP
<i>B. fragilis</i> T(B)9	-9.252	0.144	0.005	99.836	0.016	SR	PR	TP
<i>Bacteroides intestinalis</i> DSM17393	-1.296	0.398	0.005	59.267	11.246	SR	PR	TP
<i>Bacteroides ovatus</i> ATCC8483	-0.285	0.473	0.546	17.951	26.915	Non-SR	PR	FP
<i>Bacteroides pectinophilus</i> ATCC43243	-0.249	0.241	0.268	15.832	14.042	Non-SR	Non-PR	TN
<i>Bacteroides stercoris</i> ATCC43183	-0.588	0.326	0.053	33.46	15.033	Non-SR	Non-PR	TN
<i>Bacteroides thetaiotaomicron</i> 3731	-1.303	0.248	0.005	59.461	6.961	SR	PR	TP
<i>Bacteroides thetaiotaomicron</i> 7330	-1.032	0.237	0.003	51.082	8.044	SR	PR	TP
<i>Bacteroides thetaiotaomicron</i> VPI-5482	-1.252	0.155	0.006	58.006	4.511	SR	PR	TP
<i>Bacteroides uniformis</i> ATCC8492	-2.605	0.389	0.001	83.558	4.436	SR	Non-PR	FN
<i>Bacteroides xylanisolvens</i> DSM18836	-9.663	0.115	0.002	99.877	0.01	SR	PR	TP
<i>Bifidobacterium adolescentis</i> ATCC15703	-0.7	0.271	0.014	38.442	11.584	SR	Non-PR	FN
<i>Bifidobacterium breve</i> DSM20213	-9.241	0.182	0.008	99.835	0.021	SR	Non-PR	FN
<i>Blautia hansenii</i> DSM20583	-9.234	0.155	0.005	99.834	0.018	SR	Non-PR	FN
<i>Bryantia formatexigens</i> DSM14469	-0.722	0.432	0.113	39.359	18.171	Non-SR	PR	FP
<i>Clostridium asparagiforme</i> DSM15981	-9.184	0.203	0.01	99.828	0.024	SR	Non-PR	FN
<i>Clostridium bolteae</i> ATCCBAA-613	-7.113	0.611	0.005	99.277	0.306	SR	Non-PR	FN
<i>Clostridium difficile</i> 120	-6.039	0.703	0.013	98.479	0.741	SR	PR	TP
<i>Clostridium ramosum</i> DSM1402	-9.046	0.169	0.006	99.811	0.022	SR	PR	TP
<i>Clostridium scindens</i> ATCC35704	-9.064	0.324	0.004	99.813	0.042	SR	Non-PR	FN
<i>Clostridium spiroforme</i> DSM1552	-2.478	0.572	0.001	82.055	7.119	SR	Non-PR	FN
<i>Clostridium sporogenes</i> ATCC15579	-9.072	0.158	0.006	99.814	0.02	SR	PR	TP
<i>Clostridium symbiosum</i> ATCC14940	-9.256	0.209	0.009	99.836	0.024	SR	Non-PR	FN
<i>Collinsella aerofaciens</i> ATCC25986	-6.629	0.628	0.046	98.99	0.44	SR	PR	TP
<i>Collinsella intestinalis</i> DSM13280	-8.916	0.118	0.003	99.793	0.017	SR	Non-PR	FN
<i>Coprococcus comes</i> ATCC27758	-9.182	0.199	0.009	99.828	0.024	SR	Non-PR	FN
<i>Dorea formicigenerans</i> ATCC27755	-4.071	0.57	0.015	94.051	2.351	SR	Non-PR	FN
<i>Edwardsiella tarda</i> ATCC23685	-0.107	0.287	0.722	7.125	18.483	Non-SR	PR	FP
<i>Eggerthella lenta</i> ATCC25559	-0.435	0.217	0.038	26.042	11.107	SR	PR	TP
<i>Enterobacter cancerogenus</i> ATCC35316	-0.853	0.579	0.076	44.621	22.214	Non-SR	PR	FP
<i>Enterococcus faecalis</i> V583	-8.61	0.228	0.01	99.744	0.04	SR	PR	TP
<i>Escherichia coli</i> K-12	-0.714	0.331	0.038	39.057	13.995	SR	PR	TP
<i>Eubacterium bifforme</i> DSM3989	-8.927	0.098	0.008	99.795	0.014	SR	Non-PR	FN
<i>Eubacterium hallii</i> DSM3353	-9.031	0.381	0.028	99.809	0.05	SR	Non-PR	FN
<i>Eubacterium rectale</i> ATCC33656	-9.002	0.322	0.022	99.805	0.044	SR	PR	TP
<i>Eubacterium ventriosum</i> ATCC27560	-4.653	0.827	0.051	96.024	2.278	Non-SR	Non-PR	TN
<i>Odoribacter splanchnius</i>	-7.892	0.744	0.004	99.579	0.217	SR	PR	TP
<i>Parabacteroides distasonis</i> ATCC8503	-1.007	0.298	0.022	50.253	10.272	SR	Non-PR	FN
<i>Parabacteroides johnsonii</i> DSM18315	-0.529	0.281	0.123	30.702	13.51	Non-SR	Non-PR	TN
<i>Parabacteroides merdae</i> ATCC43184	-0.749	0.208	0.006	40.508	8.593	SR	Non-PR	FN
<i>Pretovella copri</i> DSM18205	-8.693	0.41	0.015	99.758	0.069	SR	Non-PR	FN
<i>Proteus penneri</i> ATCC35198	-1.657	0.313	0.009	68.289	6.884	SR	PR	TP
<i>Providencia alcalifaciens</i> DSM30120	-0.379	0.247	0.108	23.094	13.183	Non-SR	PR	FP
<i>Providencia rettgeri</i> DSM1131	-0.205	0.204	0.25	13.245	12.273	Non-SR	PR	FP
<i>Providencia stuartii</i> ATCC25827	-0.072	0.246	0.807	4.854	16.212	Non-SR	PR	FP
<i>Roseburia intestinalis</i> L1-82	-8.876	0.156	0.006	99.787	0.023	SR	Non-PR	FN
<i>Ruminococcus gnavus</i> ATCC29149	-8.639	0.045	0	99.749	0.008	SR	Non-PR	FN
<i>Ruminococcus lactaris</i> ATCC29176	-9.522	0.145	0.005	99.864	0.014	SR	Non-PR	FN
<i>Ruminococcus torques</i> ATCC27756	-2.384	0.298	0.016	80.841	3.961	SR	PR	TP
<i>Salmonella Typhimurium</i> LT2	-0.673	0.712	0.252	37.287	30.936	Non-SR	PR	FP
<i>Subdoligranulum variabile</i> DSM15176	-8.854	0.189	0.008	99.784	0.028	SR	Non-PR	FN
<i>Victivallis vadensis</i> ATCC BAA-548	-1.844	0.392	0.004	72.146	7.574	SR	Non-PR	FN



TABLE 2  
Summarized results of systematic Zimmermann et al. (2019) comparison  
This table displays the summarized results of the systematic comparison of predicted sulfasalazine reducers to experimentally confirmed sulfasalazine reducers reported by Zimmermann et al. (2019).


	PR	Non-PR
SR	38.8% (26/67) <sup>a</sup>	40.3% (27/67) <sup>b</sup>
Non-SR	11.9% (8/67) <sup>c</sup>	9.0% (6/67) <sup>d</sup>

<sup>a</sup>The number of true positives.  
<sup>b</sup>The number of false negatives.  
<sup>c</sup>The number of true false positives.  
<sup>d</sup>The number of true negatives.

Although azoreductase activity has been identified in several prominent phyla of the human gut microbiota (Zimmermann et al., 2019) and appears to be ubiquitous across healthy individuals (Javdan et al., 2020), the prevalence, abundance, and distribution of azoreductases have not been systematically examined in the human gut microbiome of healthy individuals nor in individuals living with IBD. In this work, we curated and compiled known azoreductase genes (Fig. 2), searched for azoreductase gene families across a nonredundant set of 4644 human gut bacterial genomes (Almeida et al., 2020), and identified 1958 putative azo-reducing species (Fig. 3). The systematic comparison of our search results to recent experimental evidence of sulfasalazine reduction by

prominent gut bacteria (Table 1, Table 2) indicates a disconnect between the current state of azoreductase annotation and experimental evidence of sulfasalazine reduction. Interestingly, the majority (77.1%, 27/35) of incorrectly predicted sulfasalazine-reducing strains are false negatives, meaning these strains did not return a significant hit to an azoreductase gene from the homolog search step but do, in fact, reduce sulfasalazine in vitro. This inconsistency between annotated azoreductases and experimental evidence of azo reduction suggests that many prominent bacterial strains of the human gut microbiome may encode and express previously uncharacterized azoreductase genes. These genes likely serve other endogenous roles such as nitro reduction (Liu et al., 2007; Chalansonnet et al., 2017) and quinone oxidoreduction (Leelakriangsak et al., 2008; Liu et al., 2008; Ryan et al., 2010a; Ryan et al., 2010b; Ryan et al., 2014), with the azo reduction being a side mechanism that these enzymes crossfunctionally participate in.

We next sought to report the relative abundance and expression of azoreductases in the human gut microbiome for healthy controls and IBD patients. Our analysis of 1558 metagenomic samples from 326 individuals across healthy, UC, and CD patient cohorts showed that clade I, II, III, IVa, IVb, mdaB, and yieF azoreductases are significantly more abundant in the gut microbiome compared with the other azoreductases examined in this study (Fig. 4, A and B). We also examined the



**Fig. 6.** Three putative azo-reducing strains of *F. nucleatum* degrade Acid Orange 7 in vitro. The absorbance of light at 550 nm (corresponding to the absorbance spectra of Acid Orange 7) was measured in cultures of *F. nucleatum*, *B. fragilis*, and *C. clostridioforme* isolate cultures. *F. nucleatum* strains were grown in BHI media and were compared with BHI-blank control mixture, whereas *B. fragilis* and *C. clostridioforme* strains were grown in YCFA media and were thus compared with a YCFA-blank. Each strain was grown and tested in biologic and technical triplicates. Each data point on the plot above is the average of three technical replicates from a single biologic replicate per strain. Please see *Materials and Methods* for more details regarding our experimental methodology. Asterisks indicate statistical significance calculated via two-sided *t* tests (\**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001).

expression of azoreductases by the human gut microbiota and found that, with the exception of clade IVb, expression levels of azoreductases roughly match with their corresponding genomic abundance (Fig. 4C). The incongruence of clade IVb abundance and expression levels suggests that, when feasible, shotgun metagenomic sequencing of stool samples should be performed in parallel with metatranscriptomic sequencing to better understand the functional landscape of the gut microbiome and the relative contributions of different azoreductases to overall azo reduction. We also sought to examine the relative abundance of known and putative azo-reducing bacteria in healthy, UC, and CD patients over time. We found that the relative abundance of known and putative azo-reducing bacteria is significantly ( $P = 0.002$ ) higher in individuals with CD and is modestly ( $P = 0.06$ ) higher in individuals with UC compared with healthy controls (Fig. 5). This bodes well for the future of azo-bonded prodrug development because these therapies are intended to treat individuals afflicted with UC and CD. However, the cumulative relative abundance of known and putative azo-reducing bacteria fluctuates over time (Fig. 5B), and future studies should explore whether there exists some minimum necessary abundance of azo-reducing species for adequate prodrug metabolism and activation.

Finally, we tested the reduction of the azo-bonded dye Acid Orange 7 by three strains of *F. nucleatum* alongside positive control strains of *B. fragilis* and *C. clostridioforme* (Fig. 6). *F. nucleatum* is positively correlated with colorectal cancer (Marchesi et al., 2011; Kostic et al., 2012), is present in and on cancerous tissue (Castellari et al., 2012), and possibly contributes to the etiology of the disease (McCoy et al., 2013; Rubinstein et al., 2013; Han, 2015). We found that *F. nucleatum* CTI-06, *F. nucleatum* subsp. *animalis* D11, and *F. nucleatum* subsp. *polymorphum* all significantly reduce Acid Orange 7 in vitro, indicating the encoding and activity of azoreductases in these strains of *F. nucleatum*. The *F. nucleatum* reference strain present in UHGG received significant hits to the mdaB (E-value =  $4.20 \times 10^{-13}$ ) and yieF (E-value =  $1.40 \times 10^{-23}$ ) HMMs and, thus, represents an accurately predicted azo-reducing bacteria (Supplemental Table 3). The identification and characterization of these, and possibly other, *F. nucleatum* azoreductases could lead to the eventual development of an azo-bonded colorectal cancer therapeutic designed specifically to activate in the presence of *F. nucleatum* on the surface of colonic tumors.

*B. fragilis* is a known reducer of azo dyes including Acid Orange 7 (this study), Amaranth, Orange II, and Tartrazine (Bragger et al., 1997), as well as of the quinone menadione (Ito et al., 2020). Additionally, many *B. fragilis* strains have been shown to be potent reducers of sulfasalazine in vitro (Zimmermann et al., 2019). Although we did identify a significant (E-value <  $1 \times 10^{-45}$ ) hit to the clade IVa HMM in the two *B. fragilis* reference strains present in UHGG (Supplemental Table 3), there may be other *B. fragilis* genes or operons that exhibit azoreductase activity. Ito et al. (2020) described two NADH:quinone oxidoreductase operons, NQR and NUO, and one NADH:quinone oxidoreductase gene, *ndh2*, capable of reducing the quinone menadione. Recall that bacterial quinone oxidoreductases are often crossreactive with azo compounds and have even been proposed to be a part of the same FMN-dependent superfamily of NAD(P)H utilizing oxidoreductase enzymes (Ryan et al., 2014). Future studies are required to confirm or deny that NQR, NUO, and *ndh2* are hitherto uncharacterized azoreductases contributing to the complete azo reduction of sulfasalazine by *B. fragilis* shown in Zimmerman et al. (2019).

Of the seven bacterial strains tested for reduction of Acid Orange 7, the two *C. clostridioforme* strains exhibited by far the most effective reduction of Acid Orange 7 (Fig. 6). Although *C. clostridioforme* is a known azo dye reducer (Raffi and Cerniglia, 1990; Nakamura et al., 2002; Xu et al., 2010), neither of the two reference strains present in UHGG recruited significant alignments to known azoreductase gene

families curated in the homolog search step of this work (Supplemental Table 3). This could be the result of either 1) strain-level variation between the reference strains and those tested with Acid Orange 7 in this study or 2) the presence and activity of one or more uncharacterized azoreductases in *C. clostridioforme*. In either case, further research including a comparative genomics analysis and gene knockout experiment on various strains of *C. clostridioforme* could lead to an improved understanding of gut microbial azo reduction.

This study has two primary limitations. 1) The E-value and percent of alignment thresholds for determining a putative azoreductase in the homolog search step are not absolute but rather are designed to strike a balance between identifying spurious homologs and missing the identification of true azoreductase homologs. This is an inherent limitation of studies requiring hard cutoffs for homolog classification and, thus, is very difficult to avoid. 2) Bacterial azoreductases exhibit different substrate specificities (Bin et al., 2004; Deller et al., 2006; Sugiura et al., 2006; Joshi et al., 2008; Ryan et al., 2010a, ; Mendes et al., 2011; Lang et al., 2013) and, thus, have varying affinities for different azo prodrugs as well as azo dyes. Though we show a significant reduction of Acid Orange 7 by three strains of *F. nucleatum* in this work, future experiments showing the reduction of azo drugs such as sulfasalazine would further bolster the hypothesis that *F. nucleatum* encodes and expresses one or more uncharacterized azoreductases.

In conclusion, we show that known azoreductases are widely distributed in the human gut microbiome and that there are likely many more uncharacterized azoreductases encoded and expressed in the human gut microbiome. These results both 1) bolster previous findings suggesting the ubiquity of azo-reduction in the gut microbiome (Javdan et al., 2020) and 2) suggest the presence and activity of many hitherto uncharacterized azoreductases in the human gut microbiome. The list of false negative strains identified in our systematic comparison analysis can serve as a resource for future studies focused on identifying azoreductases encoded by the human gut microbiome (Table 1). Overall, this work describes the abundance and distribution of known azoreductases in the human gut microbiome and motivates the need for future studies focused on annotating hitherto uncharacterized azoreductases encoded in the human gut microbiome. Further validation and annotation of putative azoreductases encoded by prominent members of the gut flora such as *B. fragilis*, *F. nucleatum*, and *C. clostridioforme*, are important for functional characterization of azo reduction by the human gut microbiome and for the future of azo prodrug development.

## Authorship Contributions

*Participated in research design:* Braccia, Minabou Ndjite, Jiang, Pop, Hall.

*Conducted experiments:* Minabou Ndjite, Weiss, Levy, Abeyasinghe.

*Performed data analysis:* Braccia, Minabou Ndjite.

*Wrote or contributed to the writing of the manuscript:* Braccia, Minabou Ndjite, Weiss, Levy, Abeyasinghe, Jiang, Pop, Hall.

## References

- Abed J, Emgård JEM, Zamir G, Feroja M, Almog G, Grenov A, Sol A, Naor R, Pikarsky E, Atlan KA, et al. (2016) Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. *Cell Host Microbe* 20:215–225.
- Abu-Ali GS, Mehta RS, Lloyd-Price J, Mallick H, Brannack T, Ivey KL, Drew DA, DuLong C, Rimm E, Izard J, et al. (2018) Metatranscriptome of human faecal microbial communities in a cohort of adult men. *Nat Microbiol* 3:356–366.
- Almeida A, Nayfach S, Boland M, Strozzi F, Beracochea M, Shi ZJ, Pollard KS, Sakharova E, Parks DH, Hugenholtz P, et al. (2021) A unified catalog of 204,938 reference genomes from the human gut microbiome. *Nat Biotechnol* 39:105–114.
- Bashir A, Miskeen AY, Bhat A, Fazili KM, and Ganai BA (2015) Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. *Eur J Cancer Prev* 24:373–385.
- Bates D, Mächler M, Bolker B, and Walker S (2014) Fitting Linear Mixed-Effects Models Using lme4. *J Stat Softw* 67:1–48. DOI: <http://arxiv.org/abs/1406.5823>.
- Bay HH, Lim CK, Kee TC, Ware I, Chan GF, Shahir S, and Ibrahim Z (2014) Decolourisation of Acid Orange 7 recalcitrant auto-oxidation coloured by-products using an acclimatised mixed bacterial culture. *Environ Sci Pollut Res Int* 21:3891–3906.

- Bin Y, Jiti Z, Jing W, Cuihong D, Hongman H, Zhiyong S, and Yongming B (2004) Expression and characteristics of the gene encoding azoreductase from *Rhodobacter sphaeroides* AS1.1737. *FEMS Microbiol Lett* **236**:129–136.
- Blümel S and Stolz A (2003) Cloning and characterization of the gene coding for the aerobic azoreductase from *Pigmentiphaga kullae* K24. *Appl Microbiol Biotechnol* **62**:186–190.
- Blümel S, Knackmuss H-J, and Stolz A (2002) Molecular cloning and characterization of the gene coding for the aerobic azoreductase from *Xenophilus azovorans* KF46F. *Appl Environ Microbiol* **68**:3948–3955.
- Bragger JL, Lloyd AW, Soozandehfar SH, Bloomfield SF, Marriott C, and Martin GP (1997) Investigations into the Azo Reducing Activity of a Common Colonic Microorganism. *Int J Pharm* **157**:61–71 DOI: 10.1016/S0378-5173(97)00214-7.
- Brown JP (1981) Reduction of polymeric azo and nitro dyes by intestinal bacteria. *Appl Environ Microbiol* **41**:1283–1286.
- Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, et al. (2012) *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res* **22**:299–306.
- Cerniglia CE, Freeman JP, Franklin W, and Pack LD (1982) Metabolism of azo dyes derived from benzidine, 3,3'-dimethyl-benzidine and 3,3'-dimethoxybenzidine to potentially carcinogenic aromatic amines by intestinal bacteria. *Carcinogenesis* **3**:1255–1260.
- Chalansonnet V, Mercier C, Oregna S, and Gilbert C (2017) Identification of *Enterococcus faecalis* enzymes with azoreductases and/or nitroreductase activity. *BMC Microbiol* **17**:126.
- Chaumeil PA, Mussig AJ, Hugenholtz P, and Parks DH (2019) GTDB-Tk: a toolkit to classify genomes with the Genome Taxonomy Database. *Bioinformatics* **36**:1925–1927.
- Chen H, Hopper SL, and Cerniglia CE (2005) Biochemical and molecular characterization of an azoreductase from *Staphylococcus aureus*, a tetrameric NADPH-dependent flavoprotein. *Microbiology (Reading)* **151**:1433–1441.
- Chen H, Wang RF, and Cerniglia CE (2004) Molecular cloning, overexpression, purification, and characterization of an aerobic FMN-dependent azoreductase from *Enterococcus faecalis*. *Protein Expr Purif* **34**:302–310.
- Chen S, Zhou Y, Chen Y, and Gu J (2018) fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* **34**:i884–i890.
- Cohen RD, Woseth DM, Thisted RA, and Hanauer SB (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. *Am J Gastroenterol* **95**:1263–1276.
- Cominelli F, Nast CC, Duchini A, and Lee M (1992) Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. *Gastroenterology* **103**:65–71.
- Deller S, Sollner S, Trenker-El-Toukhy R, Jelesarov I, Gübitz GM, and Macheroux P (2006) Characterization of a thermostable NADPH:FMN oxidoreductase from the mesophilic bacterium *Bacillus subtilis*. *Biochemistry* **45**:7083–7091.
- Saha JR, Butler Jr VP, Neu HC, and Lindenbaum J (1983) Digoxin-inactivating bacteria: identification in human gut flora. *Science* **220**:325–327.
- Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res* **32**:1792–1797.
- Eslami M, Amoozegar MA, and Asad S (2016) Isolation, cloning and characterization of an azoreductase from the halophilic bacterium *Halomonas elongata*. *Int J Biol Macromol* **85**:111–116.
- Feng J, Cerniglia CE, and Chen H (2012) Toxicological significance of azo dye metabolism by human intestinal microbiota. *Front Biosci (Elite Ed)* **4**:568–586.
- Finn RD, Clements J, Arndt W, Miller BL, Wheeler TJ, Schreiber F, Bateman A, and Eddy SR (2015) HMMER web server: 2015 update. *Nucleic Acids Res* **43** (W1):W30–W38.
- Foppoli A, Maroni A, Moutaharik S, Melocchi A, Zema L, Palugan L, Cerea M, and Gazzaniga A (2019) In vitro and human pharmacocintigraphic evaluation of an oral 5-ASA delivery system for colonic release. *Int J Pharm* **572**:118723.
- Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McVey LJ, et al. (2019) Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nat Microbiol* **4**:293–305.
- Friend DR (2005) New oral delivery systems for treatment of inflammatory bowel disease. *Adv Drug Deliv Rev* **57**:247–265.
- Gerlt JA, Bouvier JT, Davidson DB, Imker HJ, Sadkhin B, Slater DR, and Whalen KL (2015) Enzyme Function Initiative-Enzyme Similarity Tool (EFI-EST): A web tool for generating protein sequence similarity networks. *Biochim Biophys Acta* **1854**:1019–1037.
- Gonçalves AMD, Mendes S, de Sanctis D, Martins LO, and Bento I (2013) The crystal structure of *Pseudomonas putida* azoreductase – the active site revisited. *FEBS J* **280**:6643–6657.
- Gustafsson A, Andersson M, Lagerstedt K, Lönnroth C, Nordgren S, and Lundholm K (2010) Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2. *Int J Oncol* **36**:469–478.
- Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, and Turnbaugh PJ (2013) Predicting and manipulating cardiac drug inactivation by the human gut bacterium *Eggerthella lenta*. *Science* **341**:295–298.
- Han, YW (2015) *Fusobacterium nucleatum*: a commensal-turned pathogen. *Curr Opin Microbiol* **23**:141–147. DOI: 10.1016/j.mib.2014.11.013.
- Ito T, Gallegos R, Matano LM, Butler NL, Hantman N, Kaili M, Coyne MJ, Comstock LE, Malamy MH, and Barquera B (2020) Genetic and Biochemical Analysis of Anaerobic Respiration in *Bacteroides fragilis* and Its Importance In Vivo. *mBio* **11**:e03238–19. DOI: 10.1128/mBio.03238-19.
- Jaydan B, Lopez JG, Chankhamjon P, Lee YJ, Hull R, Wu Q, Wang X, Chatterjee S, and Donia MS (2020) Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. *Cell* **181**:1661–1679.e22.
- Joshi T, Iyengar L, Singh K, and Garg S (2008) Isolation, identification and application of novel bacterial consortium TJ-1 for the decolorization of structurally different azo dyes. *Bioresour Technol* **99**:7115–7121.
- Peters U, Falk LC, and Kalman SM (1978) Digoxin metabolism in patients. *Arch Intern Med* **137**:1074–1076.
- Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, et al. (2012) Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Res* **22**:292–298.
- Kuznetsova A, Brockhoff PB, and Christensen RHB (2017) lmerTest Package: Tests in Linear Mixed Effects Models. *J Stat Softw* **82**:1–26 DOI: 10.18637/jss.v082.i13.
- Lang W, Sirisanasaneyakul S, Ngwisakul L, Mendes S, Martins LO, Okuyama M, and Kimura A (2013) Characterization of a new oxygen-insensitive azoreductase from *Brevibacillus laterosporus* TISTR1911: toward dye decolorization using a packed-bed metal affinity reactor. *Bioresour Technol* **150**:298–306.
- Langmead B and Salzberg SL (2012) Fast gapped-read alignment with bowtie 2. *Nat Methods* **9**:357–359. DOI: 10.1038/nmeth.1923.
- Leelakriangsak M, Huyen NT, Töwe S, van Duy N, Becher D, Hecker M, Antelmann H, and Zuber P (2008) Regulation of quinone detoxification by the thiol stress sensing DUF24/MarR-like repressor, YodB in *Bacillus subtilis*. *Mol Microbiol* **67**:1108–1124.
- Leticia I and Bork P (2019) Interactive Tree Of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res* **47** (W1):W256–W259.
- Liu G, Zhou J, Jin R, Zhou M, Wang J, Lu H, and Qu Y (2008) Enhancing survival of *Escherichia coli* by expression of azoreductase AZR possessing quinone reductase activity. *Appl Microbiol Biotechnol* **80**:409–416.
- Liu G, Zhou J, Lv H, Xiang X, Wang J, Zhou M, and Qv Y (2007) Azoreductase from *Rhodobacter sphaeroides* AS1.1737 is a flavodoxin that also functions as nitroreductase and flavin mononucleotide reductase. *Appl Microbiol Biotechnol* **76**:1271–1279.
- Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, and Hawkey CJ (1991) 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. *Gut* **32**:50–54.
- Marchesi JR, Dutilleul BE, Hall N, Peters WHM, Roelofs R, Boleij A, and Tjalsma H (2011) Towards the human colorectal cancer microbiome. *PLoS One* **6**:e20447.
- Ruiz JFM, Kedziora K, Keogh B, Maguire J, Reilly M, Windle H, Kelleher DP, and Gilmer JF (2011) A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors. *Bioorg Med Chem Lett* **21**:6636–6640.
- Matsumoto K, Mukai Y, Ogata D, Shozui F, Ndoko JM, Taguchi S, and Ooi T (2010) Characterization of thermostable FMN-dependent NADH azoreductase from the moderate thermophile *Geobacillus stearothermophilus*. *Appl Microbiol Biotechnol* **86**:1431–1438. DOI: 10.1007/s00253-009-2351-7.
- McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, and Keku TO (2013) *Fusobacterium* is associated with colorectal adenomas. *PLoS One* **8**:e53653.
- Mendes S, Pereira L, Batista C, and Martins LO (2011) Molecular determinants of azo reduction activity in the strain *Pseudomonas putida* MET94. *Appl Microbiol Biotechnol* **92**:393–405.
- Mercier C, Chalansonnet V, Oregna S, and Gilbert C (2013) Characteristics of major *Escherichia coli* reductases involved in aerobic nitro and azo reduction. *J Appl Microbiol* **115**:1012–1022.
- Misal SA, Lingojwar DP, Lokhande MN, Lokhande PD, and Gawai KR (2014) Enzymatic transformation of nitro-aromatic compounds by a flavin-free NADH azoreductase from *Lysinibacillus sphaericus*. *Biotechnol Lett* **36**:127–131.
- Misal SA, Lingojwar DP, Shinde RM, and Gawai KR (2011) Purification and characterization of azoreductase from alkaliphilic strain *Bacillus badius*. *Process Biochem* **46**:1264–1269. DOI: 10.1016/j.procbio.2011.02.013.
- Morrison JM, Wright CM, and John GH (2012) Identification, Isolation and Characterization of a Novel Azoreductase from *Clostridium Perfringens*. *Anaerobe* **18**:229–234. DOI: 10.1016/j.anaerobe.2011.12.006.
- Nachiyar CV and Rajakumar GS (2005) Purification and Characterization of an Oxygen Insensitive Azoreductase from *Pseudomonas Aeruginosa*. *Enzyme Microb Technol* **36**:503–509 DOI: 10.1016/j.enzmictec.2004.11.015.
- Nakamura J, Kubota Y, Miyaoka M, Saitoh T, Mizuno F, and Benno Y (2002) Comparison of four microbial enzymes in *Clostridia* and *Bacteroides* isolated from human feces. *Microbiol Immunol* **46**:487–490.
- Nakanishi M, Yatome C, Ishida N, and Kitade Y (2001) Putative ACP phosphodiesterase gene (acpD) encodes an azoreductase. *J Biol Chem* **276**:46394–46399.
- Nielsen OH (1982) Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. *Scand J Gastroenterol* **17**:389–393.
- Ooi T, Shibata T, Sato R, Ohno H, Kinoshita S, Thuoc TL, and Taguchi S (2007) An azoreductase, aerobic NADH-dependent flavoprotein discovered from *Bacillus sp.*: functional expression and enzymatic characterization. *Appl Microbiol Biotechnol* **75**:377–386.
- Patro R, Duggal G, Love MI, Irizarry RA, and Kingsford C (2017) Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods* **14**:417–419.
- Peppercom MA and Goldman P (1972) The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. *J Pharmacol Exp Ther* **181**:555–562.
- Peppercom MA and Goldman P (1973) Distribution studies of salicylazosulfapyridine and its metabolites. *Gastroenterology* **64**:240–245.
- Perrotta C, Pellegrino P, Moroni E, De Palma C, Cervia D, Danelli P, and Clementi E (2015) 5-Aminosalicylic Acid: an update for the reappraisal of an old drug. *Gastroenterol Res Pract* **2015**:456895.
- Proctor L and Huttenhower C; Integrative HMP (iHMP) Research Network Consortium (2019) The Integrative Human Microbiome Project. *Nature* **569**:641–648.
- Rachmilewitz D, Karmeli F, Schwartz LW, and Simon PL (1992) Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. *Gut* **33**:929–932.
- Raffi F and Cerniglia CE (1990) An Anaerobic Nondenaturing Gel Assay for the Detection of Azoreductase from Anaerobic Bacteria. *J Microbiol Methods* **12**:139–148. DOI: 10.1016/0167-7012(90)90024-Z.
- Raffi F and Cerniglia CE (1995) Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. *Environ Health Perspect* **103** (Suppl 5):17–19.
- Raffi F, Franklin W, and Cerniglia CE (1990) Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora. *Appl Environ Microbiol* **56**:2146–2151.
- Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, and Han YW (2013) *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. *Cell Host Microbe* **14**:195–206.
- Ruiz JFM, Kedziora K, Windle H, Kelleher DP, and Gilmer JF (2011) Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models. *J Pharm Pharmacol* **63**:806–816. DOI: 10.1111/j.2042-7158.2011.01289.x.
- Ryan A, Kaplan E, Nebel J-C, Polycarpou E, Crescente V, Lowe E, Preston GM, and Sim E (2014) Identification of NAD(P)H quinone oxidoreductase activity in azoreductases from *P. aeruginosa*: azoreductases and NAD(P)H quinone oxidoreductases belong to the same FMN-dependent superfamily of enzymes. *PLoS One* **9**:e8551.
- Ryan A, Laurieri N, Westwood I, Wang C-J, Lowe E, and Sim E (2010a) A novel mechanism for azoreduction. *J Mol Biol* **400**:24–37.
- Ryan A, Wang C-J, Laurieri N, Westwood I, and Sim E (2010b) Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. *Protein Cell* **1**:780–790.



- Sousa T, Yadav V, Zann V, Borde A, Abrahamsson B, and Basit AW (2014) On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid. *J Pharm Sci* **103**:3171–3175.
- Spanogiannopoulos P, Bess EN, Carmody RN, and Turnbaugh PJ (2016) The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. *Nat Rev Microbiol* **14**:273–287.
- Sugiura W, Yoda T, Matsuba T, Tanaka Y, and Suzuki Y (2006) Expression and characterization of the genes encoding azoreductases from *Bacillus subtilis* and *Geobacillus stearothermophilus*. *Biosci Biotechnol Biochem* **70**:1655–1665.
- Suzuki H (2019) Remarkable diversification of bacterial azoreductases: primary sequences, structures, substrates, physiological roles, and biotechnological applications. *Appl Microbiol Biotechnol* **103**:3965–3978.
- Suzuki Y, Yoda T, Ruhul A, and Sugiura W (2001) Molecular cloning and characterization of the gene coding for azoreductase from *Bacillus* sp. OY1-2 isolated from soil. *J Biol Chem* **276**:9059–9065.
- Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, and Yamamoto A (2002) Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. *J Control Release* **82**:51–61.
- Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, et al. (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science* **330**:831–835. DOI: 10.1126/science.1191175.
- Weber CK, Liptay S, Wirth T, Adler G, and Schmid RM (2000) Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases  $\alpha$  and  $\beta$ . *Gastroenterology* **119**:1209–1218.
- Wickham H (2011) Ggplot2. *Wiley Interdiscip Rev Comput Stat* **3**:180–185 DOI: 10.1002/wics.147.
- Wood DE, Lu J, and Langmead B (2019) Improved metagenomic analysis with Kraken 2. *Genome Biol* **20**:257.
- Wu A-W, Gu J, Ji J-F, Li Z-F, and Xu G-W (2003) Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. *World J Gastroenterol* **9**:1990–1994.
- Wu WKK, Sung JJ, Lee CW, Yu J, and Cho CH (2010) Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. *Cancer Lett* **295**:7–16.
- Xu H, Heinze TM, Paine DD, Cerniglia CE, and Chen H (2010) Sudan azo dyes and Para Red degradation by prevalent bacteria of the human gastrointestinal tract. *Anaerobe* **16**:114–119.
- Zhang X, Ng IS, and Chang JS (2016) Cloning and characterization of a robust recombinant azoreductase from *Shewanella xiamenensis* BC01. *J Taiwan Inst Chem Eng* **61**:97–105. DOI: 10.1016/j.jtice.2016.01.002.
- Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, and Goodman AL (2019) Mapping human microbiome drug metabolism by gut bacteria and their genes. *Nature* **570**:462–467.
- Zimmermann T, Kulla HG, and Leisinger T (1982) Properties of purified Orange II azoreductase, the enzyme initiating azo dye degradation by *Pseudomonas* KF46. *Eur J Biochem* **129**:197–203.

---

**Address correspondence to:** Dr. Brantley Hall, Bioscience Research Building, Room 3219, 3126 Campus Drive, College Park, MD 20742. E-mail: brantley@umd.edu

---